Merck partners with American Cancer Society to address cancer in women
- Details
- Category: Merck Group
Merck, a leading science and technology company, and the American Cancer Society (ACS) today released a report that shows all four of the top causes of cancer deaths in women worldwide are mostly preventable or can often be detected early, when treatment is more successful.
Novartis wins two prestigious Prix Galien Foundation Awards
- Details
- Category: Novartis
Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City.
A great place to work, according to Science
- Details
- Category: Abbott
Abbott is among the best science-based companies to work for in the world. For the 13th consecutive year, the journal Science recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
AstraZeneca head and neck cancer trials
- Details
- Category: AstraZeneca
Following the recent update on clinicaltrials.gov, AstraZeneca confirms that the US FDA has placed a partial clinical hold on the enrolment of new patients with head and neck squamous cell carcinoma (HNSCC) in clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines.
Bristol-Myers Squibb reports third quarter results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2016 which were highlighted by strong sales and operating performance, and continued growth for key products including Opdivo and Eliquis . The company raised full-year guidance for 2016 and provided guidance expectations for 2017,
Bayer shows strong performance
- Details
- Category: Bayer
The Bayer Group remained on a path of growth in the third quarter of 2016 and took a major strategic step forward with the agreed acquisition of Monsanto. "The announcement that we had reached agreement to acquire Monsanto is a major strategic milestone for Bayer. We will be creating a global leader in agriculture and, at the same time, reinforcing our leadership position as a Life Science company," said Bayer Management Board Chairman Werner Baumann.
Amgen builds its digital health capabilities through investment in leading digital health incubator
- Details
- Category: Amgen
Amgen (Europe) GmbH, an affiliate of Amgen Inc. (NASDAQ:AMGN) (collectively, "Amgen") today announced an investment in eHealth Ventures, an Israel-based digital health incubator. The investment reflects Amgen's commitment to serving patients by driving innovation and sustainable healthcare through technology discovery, and recognizes the importance of Israel as a source of innovation in eHealth and digital technologies.
More Pharma News ...
- Novartis delivered solid third quarter
- Get your startup to the next level
- Roche delivers good sales growth in the first nine months of 2016
- Pfizer awarded grant to evaluate vaccine to protect newborns against group B Streptococcus infection
- FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer
- Bristol-Myers Squibb Foundation joins White House Cancer Moonshot
- Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community